The national biomarker development alliance: Confronting the poor productivity of biomarker research and development

  • Poste G
  • Compton C
  • Barker A
  • 19


    Mendeley users who have this article in their library.
  • 9


    Citations of this article.


Making precision (personalized) medicine a routine clinical reality will require a comprehensive inventory of validated biomarkers and molecular diagnostic tests to stratify disease subtypes and improve accuracy in diagnosis and treatment selection. Realization of this promise has been hindered by the poor productivity of biomarker identification and validation. This situation reflects deficiencies that are pervasive across the entire spectrum of biomarker R&D, from discovery to clinical validation and in the failure of regulatory and reimbursement policies to accommodate new classes of biomarkers. The launch of the National Biomarker Development Alliance is the culmination of a 2-year review and consultation process involving diverse stakeholders to advance standards, best practices and guidelines to enhance biomarker discovery and validation by adoption of systems-based approaches and trans-sector collaboration between academia, clinical medicine and relevant private and public sector stakeholders.

Author-supplied keywords

  • biomarkers
  • biospecimens
  • regulatory
  • reimbursement
  • standards
  • systems approaches
  • validation

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • George Poste

  • Carolyn C. Compton

  • Anna D. Barker

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free